News

Thank you for your continued use of our corporate website. Our corporate website and services had been unavailable due to system failure during the following time periods: from 12:30am to 8:10am on Wednesday, July 21, 2021 (Japan Standard Time) from 10:30pm Tuesday, July 20 to 6:10pm on Wednesday, July 21, 2021 (North America Central Standard Time) from 4:30pm on Tuesday, July 20 to 0:10am on...

-Jointly Developed by Astellas and M. Heart- -Implementing MYHOLTER II into M.Heart’s cloud-type Holter ECG Analysis service- TOKYO and Iwate, July 16, 2021 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and M. Heart Co., Ltd. (Headquarters: Iwate, President and CEO: Yoshimi Mizunuma, "M. Heart") launched "MYHOLTER II", a software for the holter analyzer...

TOKYO, July 13, 2021 – Astellas Pharma Inc. (President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that it has been named to the FTSE4Good Index Series for 10 consecutive years, as a company that is performing excellent initiatives in the areas of ESG [environmental (E), social (S), governance (G)]. Astellas has conducted various activities based on the thought that Astellas’...

Study results were selected for oral presentation at the 31st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) ASP3772 has also received FDA Breakthrough Therapy Designation CAMBRIDGE, Mass, USA, and TOKYO, Japan, July 13, 2021 -- Affinivax, Inc. ("Affinivax") and Astellas Pharma Inc. (“Astellas”) announced results from the Phase 2 clinical trial of ASP3772, a novel...

- Regular Approval Based on Overall Survival Results from Confirmatory EV-301 Trial - - First and Only FDA-Approved Therapy for Urothelial Cancer Patients Who Are Cisplatin-Ineligible and Have Previously Received One or More Prior Therapies, Based on Cohort 2 of Pivotal EV-201 Trial - TOKYO and BOTHELL, Wash.– July 9, 2021 -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D...